Literature DB >> 26659948

Association of Serum Lipids and Coronary Heart Disease in Contemporary Observational Studies.

Lisandro D Colantonio1, Vera Bittner1, Kristi Reynolds1, Emily B Levitan1, Robert S Rosenson1, Maciej Banach1, Shia T Kent1, Stephen F Derose1, Hui Zhou1, Monika M Safford1, Paul Muntner2.   

Abstract

BACKGROUND: The use of statins increased among US adults with high coronary heart disease (CHD) risk after publication of the 2001 cholesterol treatment guidelines. METHODS AND
RESULTS: We analyzed the association between lipids and CHD among 9578 REasons for Geographic And Racial Differences in Stroke (REGARDS) study participants and 346,595 Kaiser Permanente Southern California (KPSC) members with baseline lipid measurements in 2003 to 2007. We performed the same analyses among 14,590 Atherosclerosis Risk In Communities (ARIC) study participants with lipid measurements in 1987 to 1989. Analyses were restricted to blacks and whites 45 to 64 years of age without CHD who were not taking statins at baseline. Total cholesterol, high-density lipoprotein cholesterol, and triglycerides were measured at baseline. Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and ratios of total to high-density lipoprotein cholesterol and triglycerides to high-density lipoprotein cholesterol were calculated. The prevalence of diabetes mellitus, history of stroke, and antihypertensive medication use increased at higher low-density lipoprotein cholesterol in ARIC but not in REGARDS or KPSC. Over 8.9 years of follow-up, 225 CHD events occurred in REGARDS, 6547 events in KPSC, and 583 events in ARIC. After multivariable adjustment, less favorable lipid levels were associated with higher hazard ratios for CHD in ARIC. These associations were attenuated in REGARDS and KPSC. For example, the hazard ratio associated with the highest versus lowest quartile of low-density lipoprotein cholesterol (≥ 146 versus ≤ 102 mg/dL) was 1.89 (95% confidence interval, 1.42-2.51) in ARIC, 1.25 (95% confidence interval, 0.81-1.92) in REGARDS, and 1.49 (95% confidence interval, 1.38-1.61) in KPSC.
CONCLUSION: The association between lipids and CHD in contemporary studies may be attenuated by the preferential use of statins by high-risk individuals.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  coronary disease; epidemiology; follow-up studies; lipids

Mesh:

Substances:

Year:  2015        PMID: 26659948      PMCID: PMC4718875          DOI: 10.1161/CIRCULATIONAHA.115.011646

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  33 in total

1.  Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation.

Authors:  R B D'Agostino; S Grundy; L M Sullivan; P Wilson
Journal:  JAMA       Date:  2001-07-11       Impact factor: 56.272

2.  The reasons for geographic and racial differences in stroke study: objectives and design.

Authors:  Virginia J Howard; Mary Cushman; Leavonne Pulley; Camilo R Gomez; Rodney C Go; Ronald J Prineas; Andra Graham; Claudia S Moy; George Howard
Journal:  Neuroepidemiology       Date:  2005-06-29       Impact factor: 3.282

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.

Authors:  Jordan Fulcher; Rachel O'Connell; Merryn Voysey; Jonathan Emberson; Lisa Blackwell; Borislava Mihaylova; John Simes; Rory Collins; Adrienne Kirby; Helen Colhoun; Eugene Braunwald; John La Rosa; T R Pedersen; Andrew Tonkin; Barry Davis; Peter Sleight; Maria Grazia Franzosi; Colin Baigent; Anthony Keech
Journal:  Lancet       Date:  2015-01-09       Impact factor: 79.321

5.  Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community.

Authors:  Guruprasad Manjunath; Hocine Tighiouart; Hassan Ibrahim; Bonnie MacLeod; Deeb N Salem; John L Griffith; Josef Coresh; Andrew S Levey; Mark J Sarnak
Journal:  J Am Coll Cardiol       Date:  2003-01-01       Impact factor: 24.094

6.  Prevalence of cardiovascular comorbidities and utilization of evidence-based treatment strategies among statin users in a Medicare and commercial health plan.

Authors:  Herbert D Aronow; Michael P Dutro; Andreas Kuznik; James Cwengros
Journal:  Curr Med Res Opin       Date:  2009-01       Impact factor: 2.580

7.  Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls.

Authors:  Jonathan A C Sterne; Ian R White; John B Carlin; Michael Spratt; Patrick Royston; Michael G Kenward; Angela M Wood; James R Carpenter
Journal:  BMJ       Date:  2009-06-29

8.  Trends in the prevalence, awareness, treatment and control of high low density lipoprotein-cholesterol among United States adults from 1999-2000 through 2009-2010.

Authors:  Paul Muntner; Emily B Levitan; Todd M Brown; Pradeep Sharma; Hong Zhao; Vera Bittner; Stephen Glasser; Meredith Kilgore; Huifeng Yun; J Michael Woolley; Michael E Farkouh; Robert S Rosenson
Journal:  Am J Cardiol       Date:  2013-05-29       Impact factor: 2.778

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

10.  Journey in guidelines for lipid management: From adult treatment panel (ATP)-I to ATP-III and what to expect in ATP-IV.

Authors:  P G Talwalkar; C G Sreenivas; Ashish Gulati; Hemang Baxi
Journal:  Indian J Endocrinol Metab       Date:  2013-07
View more
  32 in total

1.  PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016.

Authors:  Maciej Banach; Piotr Jankowski; Jacek Jóźwiak; Barbara Cybulska; Adam Windak; Tomasz Guzik; Artur Mamcarz; Marlena Broncel; Tomasz Tomasik; Jacek Rysz; Agnieszka Jankowska-Zduńczyk; Piotr Hoffman; Agnieszka Mastalerz-Migas
Journal:  Arch Med Sci       Date:  2016-12-19       Impact factor: 3.318

2.  Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel.

Authors:  Arrigo F G Cicero; Alessandro Colletti; Gani Bajraktari; Olivier Descamps; Dragan M Djuric; Marat Ezhov; Zlatko Fras; Niki Katsiki; Michel Langlois; Gustavs Latkovskis; Demosthenes B Panagiotakos; Gyorgy Paragh; Dimitri P Mikhailidis; Olena Mitchenko; Bernhard Paulweber; Daniel Pella; Christos Pitsavos; Željko Reiner; Kausik K Ray; Manfredi Rizzo; Amirhossein Sahebkar; Maria-Corina Serban; Laurence S Sperling; Peter P Toth; Dragos Vinereanu; Michal Vrablík; Nathan D Wong; Maciej Banach
Journal:  Arch Med Sci       Date:  2017-08-04       Impact factor: 3.318

3.  [Immunity and inflammation in atherosclerosis].

Authors:  D Wolf; K Ley
Journal:  Herz       Date:  2019-04       Impact factor: 1.443

Review 4.  Red Yeast Rice for Hypercholesterolemia.

Authors:  Arrigo F G Cicero; Federica Fogacci; Maciej Banach
Journal:  Methodist Debakey Cardiovasc J       Date:  2019 Jul-Sep

5.  PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021.

Authors:  Maciej Banach; Paweł Burchardt; Krzysztof Chlebus; Piotr Dobrowolski; Dariusz Dudek; Krzysztof Dyrbuś; Mariusz Gąsior; Piotr Jankowski; Jacek Jóźwiak; Longina Kłosiewicz-Latoszek; Irina Kowalska; Maciej Małecki; Aleksander Prejbisz; Michał Rakowski; Jacek Rysz; Bogdan Solnica; Dariusz Sitkiewicz; Grażyna Sygitowicz; Grażyna Sypniewska; Tomasz Tomasik; Adam Windak; Dorota Zozulińska-Ziółkiewicz; Barbara Cybulska
Journal:  Arch Med Sci       Date:  2021-11-08       Impact factor: 3.318

6.  Engineering nanomaterials to address cell-mediated inflammation in atherosclerosis.

Authors:  Sean Allen; Yu-Gang Liu; Evan Scott
Journal:  Regen Eng Transl Med       Date:  2016-03-03

7.  LDL triglycerides, hepatic lipase activity, and coronary artery disease: An epidemiologic and Mendelian randomization study.

Authors:  Günther Silbernagel; Hubert Scharnagl; Marcus E Kleber; Graciela Delgado; Tatjana Stojakovic; Reijo Laaksonen; Jeanette Erdmann; Tuomo Rankinen; Claude Bouchard; Ulf Landmesser; Heribert Schunkert; Winfried März; Tanja B Grammer
Journal:  Atherosclerosis       Date:  2018-12-28       Impact factor: 5.162

8.  2015 Russell Ross Memorial Lecture in Vascular Biology: Protective Autoimmunity in Atherosclerosis.

Authors:  Klaus Ley
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-01-28       Impact factor: 8.311

Review 9.  Immunity and Inflammation in Atherosclerosis.

Authors:  Dennis Wolf; Klaus Ley
Journal:  Circ Res       Date:  2019-01-18       Impact factor: 17.367

10.  PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke: Data From 9 Studies of Blacks and Whites.

Authors:  Shia T Kent; Robert S Rosenson; Christy L Avery; Yii-Der I Chen; Adolfo Correa; Steven R Cummings; L Adrienne Cupples; Mary Cushman; Daniel S Evans; Vilmundur Gudnason; Tamara B Harris; George Howard; Marguerite R Irvin; Suzanne E Judd; J Wouter Jukema; Leslie Lange; Emily B Levitan; Xiaohui Li; Yongmei Liu; Wendy S Post; Iris Postmus; Bruce M Psaty; Jerome I Rotter; Monika M Safford; Colleen M Sitlani; Albert V Smith; James D Stewart; Stella Trompet; Fangui Sun; Ramachandran S Vasan; J Michael Woolley; Eric A Whitsel; Kerri L Wiggins; James G Wilson; Paul Muntner
Journal:  Circ Cardiovasc Genet       Date:  2017-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.